# Vertex Pharmaceuticals (VRTX) earnings: $3.95B in 2025

URL: https://funkfolio.com/stock/VRTX/earnings

> Vertex Pharmaceuticals (VRTX) earnings were $3.95B in fiscal 2025. Over five fiscal years it grew 7.8% a year. Year-by-year chart and table.

---

## Vertex Pharmaceuticals (VRTX) earnings

**Earnings (net income) · fiscal 2025:** $3.95B year ended Dec 31, 2025

Vertex Pharmaceuticals (VRTX) reported net income of $3.95B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$535.60M. Figures as of 18 Nov 2026, 02:45 UTC, from the company's filings with the SEC and Yahoo Finance.

### Key facts

- **Earnings (net income), fiscal 2025:** $3.95B
- **Growth, 5 years:** +7.8% a year
- **Highest on record:** $3.95B fiscal 2025
- **Lowest on record:** -$754.63M fiscal 2010
- **Fiscal years on record:** 18 2008–2025

Figures as of 18 Nov 2026, 02:45 UTC. Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

### Vertex Pharmaceuticals earnings, in more detail

Over the five fiscal years to 2025 net income grew at a compound 7.8% a year. Across the 18 fiscal years on record (2008–2025), the highest was $3.95B in fiscal 2025 and the lowest -$754.63M in fiscal 2010.

### Earnings (net income) by fiscal year

### Vertex Pharmaceuticals earnings, year by year

Vertex Pharmaceuticals (VRTX) earnings by fiscal year

| Fiscal year | Earnings (net income) | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | $3.95B | — | Dec 31, 2025 |
| 2024 | -$535.60M | 114.8% down | Dec 31, 2024 |
| 2023 | $3.62B | 9.0% up | Dec 31, 2023 |
| 2022 | $3.32B | 41.8% up | Dec 31, 2022 |
| 2021 | $2.34B | 13.6% down | Dec 31, 2021 |
| 2020 | $2.71B | 130.4% up | Dec 31, 2020 |
| 2019 | $1.18B | 43.9% down | Dec 31, 2019 |
| 2018 | $2.10B | 695.8% up | Dec 31, 2018 |
| 2017 | $263.48M | — | Dec 31, 2017 |
| 2016 | -$112.05M | — | Dec 31, 2016 |
| 2015 | -$556.33M | — | Dec 31, 2015 |
| 2014 | -$738.56M | — | Dec 31, 2014 |
| 2013 | -$445.03M | — | Dec 31, 2013 |
| 2012 | -$107.03M | 461.9% down | Dec 31, 2012 |
| 2011 | $29.57M | — | Dec 31, 2011 |
| 2010 | -$754.63M | — | Dec 31, 2010 |
| 2009 | -$642.18M | — | Dec 31, 2009 |
| 2008 | -$459.85M | — | Dec 31, 2008 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

### How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

### Earnings (net income) at health care companies of similar size

Earnings (net income) of Vertex Pharmaceuticals and comparable companies

| Company | Earnings (net income) | Fiscal year |
| --- | --- | --- |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/earnings) | $7.77B | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/earnings) | $3.61B | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/earnings) | $2.86B | 2025 |
| Vertex Pharmaceuticals VRTX | $3.95B | 2025 |
| [Medtronic MDT](https://funkfolio.com/stock/MDT/earnings) | $4.80B | 2026 |
| [Bristol-Myers Squibb BMY](https://funkfolio.com/stock/BMY/earnings) | $7.05B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Vertex Pharmaceuticals, figure by figure

- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals earnings per share (EPS)](https://funkfolio.com/stock/VRTX/eps)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals P/S ratio](https://funkfolio.com/stock/VRTX/ps-ratio)
- [Vertex Pharmaceuticals P/B ratio](https://funkfolio.com/stock/VRTX/pb-ratio)
- [Vertex Pharmaceuticals free cash flow](https://funkfolio.com/stock/VRTX/free-cash-flow)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals dividend](https://funkfolio.com/stock/VRTX/dividend)
- [Vertex Pharmaceuticals shares outstanding](https://funkfolio.com/stock/VRTX/shares-outstanding)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Vertex Pharmaceuticals cash on hand](https://funkfolio.com/stock/VRTX/cash)
- [Vertex Pharmaceuticals total assets](https://funkfolio.com/stock/VRTX/total-assets)
- [Vertex Pharmaceuticals return on equity (ROE)](https://funkfolio.com/stock/VRTX/roe)
- [Vertex Pharmaceuticals return on invested capital (ROIC)](https://funkfolio.com/stock/VRTX/roic)

[Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecard](https://funkfolio.com/stock/VRTX) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Vertex Pharmaceuticals earnings: questions and answers

**What is Vertex Pharmaceuticals's net income?**

Vertex Pharmaceuticals (VRTX) reported net income of $3.95B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$535.60M.

**What is the growth rate of Vertex Pharmaceuticals's net income?**

Over the five fiscal years to 2025 net income grew at a compound 7.8% a year.

**What are the highest and lowest net income figures on record for Vertex Pharmaceuticals?**

Across the 18 fiscal years on record (2008–2025), the highest was $3.95B in fiscal 2025 and the lowest -$754.63M in fiscal 2010.

**How is Vertex Pharmaceuticals's net income calculated?**

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

### Learn: earnings

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Revenue vs earnings vs free cash flow: what each tells you](https://funkfolio.com/learn/stocks/revenue-earnings-free-cash-flow)

  Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.
